# FIORA5 â€” V7 Capital Investment Analysis

> **Date:** 18.02.2026
> **Analyst:** VS Code / Robert Framework
> **Prompts used:** FM #4 (Comps), FM #7 (IC Memo), MC #1 (TAM), MC #2 (Competitive Landscape), MC #4 (Industry Trends), MC #5 (SWOT + Porter's Five Forces), MC #9 (Unit Economics), MC #10 (Risk Assessment), MC #12 (Executive Synthesis)
> **Prompts skipped:** FM #1 (DCF â€” pre-revenue), FM #2 (Three-Statement â€” pre-revenue), FM #3 (LBO â€” VC equity deal), FM #5 (Credit â€” no debt), MC #3 (Customer Personas â€” B2B enterprise, single decision-maker type), MC #7 (GTM â€” insufficient data), MC #8 (Customer Journey â€” B2B complex sale, insufficient data), MC #11 (Market Entry â€” not primary question)

---

## 1. EXECUTIVE SUMMARY

Fiora5 is a Romanian deep-tech startup building proprietary CPU intellectual property (IP) on the RISC-V open-source architecture, targeting ultra-low power applications in wearables, edge AI devices, and explicitly â€” defense/aerospace systems. The core technical claim is a ~50% power reduction versus ARM Cortex-M equivalents. The company is pre-revenue, pre-MVP, at demo stage, with a team of four (CEO, CTO, VP Software/PhD, Strategic Advisor). They are raising â‚¬500K at an implied cap of â‚¬8M (SAFE per deck; CLA with 8M cap + 20% discount per Edi's meeting notes â€” discrepancy unresolved).

**The investment case has three structural problems for V7 Capital specifically.** First, Fiora5 explicitly targets defense contractors (Lockheed Martin, BAE Systems, Rheinmetall) as primary customers â€” a direct conflict with V7's SHA weapons restriction. Second, the â‚¬8M cap is priced for a post-MVP company, not a demo: comparable European RISC-V IP startups raised at â‚¬3â€“6M caps pre-product, making this 2â€“3Ã— overpriced for stage. Third, the time-to-exit in semiconductor IP is structurally 10â€“15 years (Arteris: 2003â†’2021; Codasip: 2014â†’still private), incompatible with any realistic NAV event for V7's investors.

**Recommendation: PASS.** Fiora5 may be an interesting opportunity for a specialized deep-tech fund (NATO-aligned defense fund, EU Chips Act grant recipient, or a strategic corporate venture arm). It is not the right deal for V7 Capital at this stage, at this price, or given the SHA constraints.

---

## 2. ANALYSIS BY PILLAR

### 2.1 Founders â€” Score: 6.5/10

*Informed by: FM #7 (IC Memo â€” Founders section), V7 parameters F1â€“F12*

| Parameter | Score | Evidence |
|-----------|:-----:|---------|
| **F1 â€” Technical competence** | 9/10 | Petru: 10+ years semiconductor IP (rare globally). Ciprian: EPFL PhD + ex-iNoCs (acquired by Arteris â€” a verified exit). Combined, arguably the strongest technical duo a Romanian startup could assemble in this domain |
| **F2 â€” Track record / 0â†’1** | 5/10 | Ciprian has an exit (iNoCsâ†’Arteris). But iNoCs was academic spinout in Switzerland, not a commercial 0â†’1 venture in CEE. Darian (CEO) â€” zero verifiable commercial track record in semiconductor sales or enterprise BD |
| **F3 â€” Integrity** | n/a | No red flags. No reference checks available. Cannot score |
| **F4 â€” Authenticity** | 6/10 | Tone in Edi's meeting is honest about difficulty. No overselling of traction |
| **F5 â€” Learning velocity** | 7/10 | EPFL PhD + 10-year domain expert = technical learning capacity very high. Commercial learning = unknown |
| **F6 â€” Realism** | 4/10 | "6 months FPGA MVP, 18 months final product" â€” optimistic by 2â€“3Ã— for hardware IP. TRL claim of 4â€“5 likely 3â€“4. Cap 8M at demo stage = disconnected from comparable benchmarks |
| **F7 â€” Culture / team** | n/a | Insufficient data |
| **F8 â€” Resilience** | 6/10 | Staying in semiconductor IP (one of the hardest possible domains) implies resilience. No evidence of crisis navigation |
| **F9 â€” Vision** | 7/10 | Low-power edge computing thesis is coherent and well-timed. Defense addition to the vision is strategically opportunistic but SHA-problematic |
| **F10 â€” Talent attraction** | 3/10 | Romania has no semiconductor IP hub. Hiring Petru equivalents is a global talent problem. No evidence of pipeline |
| **F11 â€” Skin in the game** | 6/10 | Presumed full-time. No data on personal capital invested or equity distribution |
| **F12 â€” Complementarity** | 6/10 | Strong on technical (CTO + VP Soft). Weak on commercial execution. Darian's ability to navigate 18â€“36 month B2B enterprise sales cycles in semiconductor = unproven |

**Key founder asset:** Ciprian's exit (iNoCs â†’ Arteris) is the single most valuable signal. Arteris is a public company ($200M+ market cap) that licenses NoC (Network-on-Chip) IP â€” directly comparable domain to Fiora5's ambition. He knows how processor IP gets commercialized.

**Key founder risk:** The CEO role in semiconductor IP licensing requires building relationships at the VP Engineering / CTO level at companies like Qualcomm, NXP, or Rheinmetall over 2â€“3 years before a purchase order. There is no evidence Darian has this network or has done this before.

**Impact on asymmetry:**
- P(win) contribution: **Moderate-positive.** Technical depth is genuine. Commercial execution capacity = biggest unknown.

---

### 2.2 Company / Business Model â€” Score: 3/10

*Informed by: MC #9 (Unit Economics), FM #7 (IC Memo â€” Company section), V7 parameters C1â€“C16*

**Business model:** Fiora5 is a pure IP licensor. Revenue comes from two sources: (1) one-time licensing fees paid when a customer adopts the IP for their SoC design, and (2) royalties per chip shipped, paid annually. This is how Arm, MIPS, Codasip, and Arteris operate.

#### Target Unit Economics (Pre-Revenue â€” Modeled)

| Metric | Target | Assumption | Risk |
|--------|--------|-----------|------|
| **One-time license fee** | â‚¬100Kâ€“â‚¬500K | Low end (startup discount); Arm Cortex-M licenses at $1â€“5M | They will undercut to win first customers |
| **Royalty per chip** | â‚¬0.01â€“â‚¬1.00 | Wide range; wearables = low vol, high royalty; IoT = high vol, low royalty | Volume forecasting impossible pre-design win |
| **Sales cycle** | 12â€“36 months | Industry standard for semiconductor IP adoption | First design win = minimum 18 months after IP is proven |
| **Gross margin at scale** | 80â€“90% | IP business = near-zero COGS per license | Only achievable post-R&D recovery |
| **CAC analog** | â‚¬100â€“250K | FTE sales + FAE + conference + travel per customer | Requires dedicated BizDev hire immediately |
| **LTV per customer** | â‚¬1.0â€“2.5M | License + 5-year royalty stream (1M chips Ã— â‚¬0.20/yr) | Assumes they actually win chip design |
| **LTV:CAC** | 5â€“15x | Target range (at scale) | Cannot be validated â€” zero customers |
| **Break-even** | Year 4â€“5 | At â‚¬1â€“1.5M ARR | Requires 3â€“5 paying customers with royalty ramp |

**Revenue projection (Base Case â€” if no SHA block):**

| Year | Event | Revenue |
|------|-------|---------|
| 2026 | FPGA MVP demo â†’ first prospect conversations | â‚¬0 |
| 2027 | IP tape-out â†’ 1 LOI, no payments yet | â‚¬0 |
| 2028 | First license deal closed | â‚¬150K one-time |
| 2029 | 2nd license + royalties from deal 1 | â‚¬350K |
| 2030 | 3 customers, royalty ramp | â‚¬800K |

**Burn rate and runway:**
- Team (4 FTE + 2 hires needed): â‚¬700Kâ€“1.0M/year
- Tools (Synopsys/Cadence full commercial): â‚¬150â€“300K/year (they currently have â‚¬10K/yr non-commercial â€” this scales dramatically)
- â‚¬500K raise = **5â€“7 months runway at minimum viable burn.** Severely insufficient. Immediate follow-on needed.

**Margin of Safety: ZERO.**
The company does not generate revenue, has no recurring contracts, and cannot survive without continuous external capital. There is no floor.

**Impact on asymmetry:**
- P(win) contribution: **Negative.** No validation of any commercial claim. Business model is correct (IP licensing works), but the path from demo to first paying customer is 2+ years and capital-intensive.
- R (return) contribution: **Neutral-positive.** IP business at scale has exceptional economics. But "at scale" is 7â€“10 years away.

---

### 2.3 Industry â€” Score: 5.5/10

*Informed by: MC #1 (TAM), MC #2 (Competitive Landscape), MC #4 (Industry Trends), MC #5 (SWOT + Porter's Five Forces)*

#### Market Sizing (MC #1)

**Top-down approach:**

| Layer | Size | Notes |
|-------|:----:|-------|
| Global Semiconductor IP market (2024) | $8.5B | All IP types â€” CPU, GPU, NoC, memory controllers |
| Processor / CPU IP segment | ~$5.0B | ARM ~$2.5B, rest split across MIPS, RISC-V, others |
| RISC-V commercial IP | ~$600M (est.) | Codasip, SiFive, Andes, Nuclei + Arm competitive response |
| Low-power RISC-V (Fiora5's target) | ~$150â€“200M | Ultra-low power sub-segment (wearables, IoT, edge AI) |

**CAGR projections:**
- Global semiconductor IP market: +9% CAGR (2024â€“2029)
- RISC-V commercial market: +25â€“30% CAGR (2024â€“2028), driven by EU/India mandates, US CHIPS Act diversification, and ARM IPO premium creating cost pressure
- Low-power edge AI: +35% CAGR (2024â€“2028)

**Bottom-up approach (Wearables segment):**
- Global wearable devices shipped (2024): ~600M units
- Wearables using custom SoC with licensed CPU IP: ~15â€“20% = 90â€“120M units
- If Fiora5 captures 0.1% market share in 5 years (realistic): ~90â€“120K chips/year
- At â‚¬0.30 royalty/chip: â‚¬27â€“36K/year â€” too small to matter
- Needs **1%+ market share** to generate meaningful royalties: â‚¬270â€“360K/year

**Bottom-up approach (Defense/Aerospace):**
- Global defense electronics IP licensing: ~$500M/year (estimated, not public)
- Contracts: 2â€“3 license deals at â‚¬300â€“500K each = â‚¬600Kâ€“1.5M/year
- But: SHA conflict blocks this segment for V7

**TAM verdict:** The addressable market is real and growing. However, Fiora5's realistic SOM in a 5-year horizon (wearables only, no defense) is â‚¬500Kâ€“2M ARR â€” small enough that the company's strategic value is primarily as an acquisition target, not a standalone business.

---

#### Competitive Landscape (MC #2)

| Player | Market Share | Revenue | Funding | Threat to Fiora5 |
|--------|:---:|:---:|:---:|:---:|
| **ARM Holdings** | ~90% (embedded) | $2.5B | Public (NASDAQ: ARM) | ðŸ”´ CRITICAL |
| **SiFive** (USA) | ~5% (RISC-V) | ~$100M est. | $175M+ raised | ðŸ”´ HIGH |
| **Codasip** (CZ/DE) | ~2â€“3% (RISC-V) | ~$30M est. | $25M Series A | ðŸ”´ HIGH |
| **Andes Technology** (Taiwan) | ~1â€“2% | ~$30M | Public (Taiwan) | ðŸŸ¡ MED |
| **Nuclei System** (China) | ~1% | unknown | Chinese gov't backed | ðŸŸ¡ MED (China market) |
| **MIPS/Imagination** (UK) | <1% | declining | Private equity owned | ðŸŸ¡ LOW-MED |
| **Arm Cortex-M0+** (free) | dominant low-power | embedded in Arm fee | â€” | ðŸ”´ FREE ALTERNATIVE |

**Fiora5's claimed white space:** Ultra-low power RISC-V CPU IP with demonstrated 50% power reduction vs. ARM Cortex-M. If proven, this is a real gap â€” ARM's Cortex-M family hasn't had fundamental efficiency architecture rethink since M0+. SiFive focuses on high-performance, Codasip on automotive. The low-power wearables/edge-AI segment is underserved by serious commercial players.

**White space assessment:** Potentially real, but verification requires independent benchmarking. Founders' claims cannot be relied on without third-party silicon validation.

**Competitive moat analysis:**
- Fiora5 has: IP uniqueness (if 50% claim holds) + first-mover in sub-segment
- Fiora5 lacks: Ecosystem (toolchain, OS ports, reference designs), customer references, EDA tool certification, certification for safety-critical uses (ISO 26262, DO-178C)
- ARM's moat is 30 years of ecosystem lock-in â€” not power efficiency â€” so a genuine efficiency breakthrough does not need to beat ARM's ecosystem to find customers. It needs to find 3â€“5 early adopters willing to take ecosystem risk.

---

#### Industry Trends (MC #4)

| Trend | Impact | Timeline | Impact Rating (1â€“10) |
|-------|--------|:--------:|:--------------------:|
| RISC-V global adoption acceleration (India RISC-V mandate, EU CHIPS Act, US DoD diversification away from ARM) | Tailwind | 1â€“3 yr | 9 |
| Edge AI proliferation â†’ ultra-low power compute demand explodes (inference at sensor level) | Strong tailwind | 1â€“2 yr | 8 |
| ARM IPO (2023) â†’ higher licensing costs push OEMs to evaluate alternatives | Tailwind | ongoing | 7 |
| CHIPS Act subsidies (US/EU) for semiconductor startups including IP | Potential non-dilutive capital for Fiora5 | 1â€“3 yr | 6 |
| Wearables market slowdown (2023-2024 weak demand) | Headwind near-term | 0â€“1 yr | -5 |
| China-Taiwan geopolitical risk â†’ demand for Western-sourced CPU IP | Tailwind (long-term) | 3â€“5 yr | 7 |
| ARM pricing increase post-IPO creates pricing pressure | Tailwind | ongoing | 6 |
| VC funding contraction in deep tech (2023â€“2025) | Headwind for follow-on raises | 0â€“2 yr | -6 |

**"So what" for Fiora5:**
The macro trend is genuinely favorable. RISC-V is having its moment. The EU CHIPS Act and similar programs provide grant capital pathways that Fiora5 should be pursuing aggressively (non-dilutive) before raising venture capital. The timing on wearables is harder short-term (softening demand 2023-2024), but the edge AI thesis supersedes wearables specifically.

---

#### SWOT + Porter's Five Forces (MC #5)

**SWOT:**

| | Strengths | Weaknesses |
|--|-----------|-----------|
| **Internal** | 1. Ciprian's exit (iNoCsâ†’Arteris): domain credibility<br>2. Petru's 10+ years: rare technical depth<br>3. Proprietary architecture: no open-source encumbrance<br>4. RISC-V ISA: no royalty to pay upstream<br>5. Genuine market timing (edge AI tailwind)<br>6. IP business model: 80-90% gross margins at scale | 1. Zero revenue, zero clients, zero MVP<br>2. CEO commercial track record = unproven<br>3. Romania: no semiconductor talent pool<br>4. â‚¬500K raise = 5-7 months runway only<br>5. Cap 8M = overpriced for demo stage<br>6. Defense targeting = SHA conflict (for V7 specifically)<br>7. 50% power claim = unverified externally |
| **External** | **Opportunities** | **Threats** |
| | 1. EU CHIPS Act grants (non-dilutive capital pathway)<br>2. ARM post-IPO pricing increases alienating OEMs<br>3. Edge AI inference creating new demand for ultra-low power CPU<br>4. RISC-V community growth â†’ ecosystem building in progress<br>5. India RISC-V mandate creates new geographic market<br>6. Defense budget increases in NATO countries (if SHA resolved)<br>7. Potential acquisition target for SiFive, Codasip, or large OEM | 1. ARM responds with aggressive low-power core (Cortex-M55, Helium extensions)<br>2. RISC-V community develops open-source ultra-low power solution that commoditizes Fiora5's IP<br>3. Talent acquisition failure â†’ technical roadmap delays<br>4. EDA tool cost (Synopsys/Cadence) scales to â‚¬1M+/year for commercial development<br>5. First customer takes 36 months, not 18 â†’ cash crisis<br>6. IP litigation from ARM (ISA is open, implementation may still face claims) |

**Cross-analysis:**
- **SO strategy:** Use Ciprian's Arteris network to get introductions to 3â€“5 potential design-win customers; apply for EU CHIPS Act grants to extend runway without dilution
- **WT risk:** Technical delays + slow first customer = cash runs out before validation â†’ fatal

**Porter's Five Forces:**

| Force | Score (1â€“10) | Assessment |
|-------|:---:|---------|
| **Competitive rivalry** | 9/10 HIGH | ARM's 90% market share + SiFive + Codasip = intense. Fiora5 needs to carve a niche, not fight head-on |
| **Supplier power** | 7/10 HIGH | Synopsys and Cadence are a duopoly for EDA tools. Non-commercial licenses = â‚¬10K/yr; commercial = â‚¬200â€“500K/yr. This cost jump is a significant barrier |
| **Buyer power** | 8/10 HIGH | OEMs buying CPU IP have significant power: they can stick with ARM (known), wait for community RISC-V (free), or shop multiple vendors. Long sales cycles, RFQ process, internal teams can build their own |
| **Threat of substitution** | 7/10 HIGH | Open-source RISC-V cores (CVA6, PicoRV32, SERV) are free. Premium value must be clearly demonstrated. If open-source catches up on power efficiency, Fiora5's moat erodes |
| **Threat of new entry** | 4/10 LOW | Semiconductor IP requires 3â€“5 years of R&D and domain expertise before producing a credible core. High barrier to entry (but Fiora5 itself IS the new entrant) |

**Industry attractiveness score: 4/10.** High rivalry, high supplier power, high buyer power â€” classic "tough industry." Opportunity exists in niche positioning but is narrow and requires flawless execution.

---

### 2.4 Deal Structure â€” Score: 2/10

*Informed by: FM #4 (Comps), FM #7 (IC Memo â€” Returns), V7 parameters D1â€“D11*

#### Instrument & Terms

| Element | Deck (SAFE) | Notes (CLA) | Assessment |
|---------|:---:|:---:|---------|
| Instrument | SAFE | CLA | Discrepancy unresolved. SAFE = simpler, CLA = more investor-friendly. Must clarify before any diligence |
| Amount | â‚¬500K | â‚¬500K | Insufficient for 18-month runway (only 5-7 months at realistic burn) |
| Cap | Not stated | â‚¬8M | High for demo stage â€” see comps below |
| Discount | Not stated | 20% | Standard |
| Protective provisions | None stated | None stated | No LP, no anti-dilution, no pro-rata, no information rights â€” all standard terms missing from what was shared |

#### Comparable Company Valuations (FM #4 â€” Pre-Revenue RISC-V IP)

| Company | Stage at First Raise | Cap / Post-Money | Year | Notes |
|---------|:---:|:---:|:---:|------|
| Codasip | Pre-product academic spinout | ~â‚¬2â€“4M | 2014 | Czech/German, strong uni background |
| SiFive | MVP + first customer LoI | ~$10M | 2015 | Silicon Valley, stronger team brand |
| Andes Technology | Product in market | Higher | 2005 | Taiwan, bootstrapped first |
| iNoCs (Ciprian's company) | Research proto, academic | ~â‚¬1â€“3M est. | 2010s | Acquired by Arteris â€” exit value unknown |
| **Fiora5 ask** | Demo, zero customers | **â‚¬8M** | 2026 | 2â€“4Ã— premium vs. comparable stage |

**Implied valuation range by methodology:**

| Methodology | Low | Mid | High |
|-------------|:---:|:---:|:---:|
| Stage-comparable (pre-product CEE/EU deep tech) | â‚¬2M | â‚¬3M | â‚¬5M |
| Team quality premium (Ciprian exit) | +â‚¬0.5M | +â‚¬1M | +â‚¬1.5M |
| Technology premium (if 50% power claim verified) | +â‚¬1M | +â‚¬2M | +â‚¬3M |
| **Fair value range** | **â‚¬3.5M** | **â‚¬6M** | **â‚¬9.5M** |

**Assessment:** The â‚¬8M cap sits at the very top of a generous range, *only* if the technology claim is independently verified and the team premium is fully credited. At demo stage without external validation, â‚¬3.5â€“5M is the defensible range.

**Discrepancy flag:** SAFE vs. CLA is a material difference. In a SAFE without a cap explicitly stated, conversion dynamics at Seria A could be unfavorable to investor. This must be resolved before any term sheet discussion.

**Missing protective provisions (standard for this stage):**
- Liquidation preference 1Ã— non-participating
- Pro-rata rights for follow-on
- Information rights (quarterly at minimum)
- MFN clause
- Anti-dilution (broad-based weighted average minimum)
- Board observer right

None of these were mentioned in available materials.

---

## 3. ASYMMETRY ASSESSMENT

*Informed by: V7 formula: Return = P(win/lose) Ã— Expected Return Ã— Portfolio Allocation*

### P(win/lose) Estimate

| Factor | Weight | Score | Weighted |
|--------|:------:|:-----:|:--------:|
| Technical team quality | 25% | 7/10 | 1.75 |
| Commercial execution capacity | 25% | 3/10 | 0.75 |
| Market timing | 15% | 7/10 | 1.05 |
| Competitive positioning | 15% | 4/10 | 0.60 |
| Capital sufficiency | 10% | 2/10 | 0.20 |
| SHA compatibility (for V7) | 10% | 0/10 | 0.00 |
| **Total P(win) score** | 100% | | **4.35/10** |

**P(win) in 7 years, independent of V7 SHA: ~20â€“25%**
**P(win) for V7 specifically (SHA blocker): <5%** (requires fundamental business model pivot away from defense)

### Expected Return (if win scenario, no SHA block)

| Scenario | Probability | Revenue Year 7 | Exit Multiple | Exit Value | V7 Share (~4%) | V7 Return | MOIC |
|----------|:-----------:|:--------------:|:-------------:|:----------:|:----------------:|:---------:|:----:|
| ðŸ”´ **Fail** | 35% | â‚¬0 | 0Ã— | â‚¬0 | â‚¬0 | -â‚¬500K | 0.0Ã— |
| ðŸŸ  **Stagnation** | 30% | â‚¬500K ARR | 4Ã— revenue | â‚¬2M | â‚¬80K | -â‚¬420K | 0.2Ã— |
| ðŸŸ¡ **Base** | 20% | â‚¬2M ARR | 5Ã— revenue | â‚¬10M | â‚¬400K | -â‚¬100K | 0.8Ã— |
| ðŸŸ¢ **Bull** | 10% | â‚¬5M ARR | 7Ã— revenue | â‚¬35M | â‚¬1.4M | +â‚¬900K | 2.8Ã— |
| ðŸŸ¢ðŸŸ¢ **M&A exit** | 5% | Strategic asset | â€” | â‚¬50â€“100M | â‚¬2â€“4M | +â‚¬1.5â€“3.5M | 3â€“7Ã— |

**Expected MOIC (probability-weighted, no SHA block, V7 ~4% at â‚¬500K investment):**

```
E[MOIC] = 0.35Ã—0 + 0.30Ã—0.2 + 0.20Ã—0.8 + 0.10Ã—2.8 + 0.05Ã—5.0
        = 0 + 0.06 + 0.16 + 0.28 + 0.25
        = 0.75Ã—
```

**Expected MOIC: 0.75Ã— â€” negative expected value even before SHA constraint.**

The math doesn't work even in the scenario where V7 could legally invest. The combination of high failure probability + long timeline + small revenue at exit + thin ownership stake = negative expected value at â‚¬500K entry.

### Asymmetry Map

```
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
           P(win/lose)              Expected Return (R)
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

  ðŸŸ¢ Technical team: genuine depth   ðŸŸ¢ IP model: 80-90% GM at scale
  ðŸ”´ SHA conflict: BLOCKER           ðŸ”´ Negative EV at current cap
  ðŸ”´ Zero commercial validation      ðŸ”´ Timeline 10-15 years
  ðŸ”´ Underfunded (5-7 mo runway)     ðŸ”´ Small SOM â†’ small exit unless M&A
  ðŸ”´ GTM unproven in hard domain     ðŸŸ¡ RISC-V tailwind is real
  ðŸ”´ P(win) overall ~20-25%          ðŸŸ¡ M&A optionality exists (SiFive,
  ðŸ”´ P(win) for V7 <5%                  Codasip, defense primes)
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

  Expected MOIC (no SHA block): 0.75Ã— â€” NEGATIVE EV
  Expected MOIC (with SHA block): ~0Ã— â€” investment not possible

  ðŸ”´ ASYMMETRY NEGATIVE â€” downside dominates
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## 4. RISK ANALYSIS

*Informed by: MC #10 (Risk Assessment & Scenario Planning)*

### Risk Matrix â€” Top 15 Risks

| # | Risk | Category | Prob (1â€“5) | Impact (1â€“5) | Score | EWI | Mitigation |
|---|------|----------|:---:|:---:|:---:|------|-----------|
| 1 | SHA conflict â€” defense customers incompatible with V7 SHA | Regulatory | 5 | 5 | **25** | Fiora5 names Lockheed/BAE/Rheinmetall in deck | V7 cannot invest without fundamental pivot by Fiora5 |
| 2 | Semiconductor talent scarcity â€” cannot hire in Romania | Operational | 5 | 5 | **25** | Immediate: no engineers beyond founding team | Global remote hiring; explore university partnerships |
| 3 | First design win takes 36+ months (not 18) | Financial | 4 | 5 | **20** | No LOI / LoI after 12 months post-raise | Bridge financing; grant capital; pivot to smaller customer |
| 4 | EDA tool costs scale to â‚¬300K+/year for commercial tapeout | Financial | 4 | 4 | **16** | Tool cost grows rapidly past demo phase | Apply for EDA vendor startup programs (Cadence CDNLive, Synopsys ARC) |
| 5 | â‚¬500K runway insufficient â€” cash crisis at month 6 | Financial | 4 | 4 | **16** | Burn rate exceeds â‚¬80K/month | Raise alongside non-dilutive (EU CHIPS Act grants) |
| 6 | Technical claim (50% power reduction) fails independent benchmark | Technical | 3 | 5 | **15** | 3rd party review before closing | Require independent power analysis as diligence condition |
| 7 | ARM responds with ultra-low power Cortex-M variant | Market | 3 | 5 | **15** | ARM product announcements | Monitor ARM roadmap; Fiora5 needs 2-3 year head start |
| 8 | ITAR/export control compliance for any defense customer | Regulatory | 4 | 4 | **16** | First defense customer discussion | Legal opinion on ITAR exposure before engaging defense |
| 9 | Founding team split (4 co-founders, no vesting mentioned) | Operational | 3 | 4 | **12** | Early disagreements on direction | Require vesting schedule with 1-year cliff as deal term |
| 10 | Open-source RISC-V catches up on power efficiency | Market | 2 | 5 | **10** | Community energy reporting for low-power cores | Maintain 18-month lead on open-source alternatives |
| 11 | IP infringement claim by ARM on implementation (not ISA) | Regulatory | 2 | 5 | **10** | ARM legal threats to RISC-V companies | Freedom-to-operate IP analysis before commercialization |
| 12 | Next venture round fails â€” bridge or down round needed | Financial | 3 | 3 | **9** | Slow traction signals | Customer LOI before Series A; grant capital bridge |
| 13 | Overestimated TRL (founders say 4-5, likely 3-4) | Technical | 4 | 3 | **12** | Demo fails under scrutiny | Independent technical review of architecture |
| 14 | Synopsys/Cadence license dependency â€” cost control risk | Operational | 2 | 3 | **6** | Contract renewals | Explore open-source EDA (OpenROAD) for initial development |
| 15 | Romania regulatory risk (IP ownership, talent mobility laws) | Regulatory | 2 | 2 | **4** | No immediate signal | Legal structure review; IP held in Swiss/Luxembourg holding |

### Kill Scenarios

**Scenario 1 â€” Technical (most likely): Power claim fails.** If independent silicon benchmarking reveals the 50% claim is closer to 15-20% (common in semiconductor marketing), Fiora5 loses its only differentiator. ARM Cortex-M0+ becomes a credible substitute. Company has no path to first design win.

**Scenario 2 â€” Commercial (likely): First customer doesn't close by month 18.** Company burns through â‚¬500K in 6-7 months. Next raise fails because there is nothing to show. Unable to pay EDA licenses. Technical team fragments. Company dissolves.

**Scenario 3 â€” Structural (certain for V7): SHA conflict never resolved.** Fiora5 chooses to continue targeting defense (highest margin, strongest differentiation on defense electronics). V7 cannot follow without violating SHA. Investment blocked before it starts.

### Scenario Planning

| Scenario | Revenue Y5 | Exit | V7 MOIC | Probability |
|----------|:---:|:---:|:---:|:---:|
| **Best case** | â‚¬3â€“5M ARR | M&A by SiFive/Codasip at â‚¬30â€“50M | 2.4â€“4.0Ã— | 10% |
| **Base case** | â‚¬800Kâ€“1.2M ARR | Long journey, possible M&A at â‚¬8â€“15M | 0.6â€“1.2Ã— | 25% |
| **Worst case** | â‚¬0 | Company dissolves, capital loss | 0Ã— | 40% |
| **Black swan** | Fiora5 IP becomes standard in EU defense electronics | EU defense prime acquisition at â‚¬100â€“200M | 8â€“16Ã— | 5% |

**Black swan note:** If EU defense sovereignty push (German Zeitenwende, EU Defence Industrial Strategy) accelerates demand for non-ARM, non-US processor IP in defense electronics â€” and Fiora5 is the only European RISC-V IP company with a defense-grade product â€” an acquisition at a large premium is plausible. However, this scenario requires: (a) EU defense funding, (b) Fiora5 surviving 5+ more years, (c) V7 SHA being amended (which requires LP consent). Extremely speculative.

---

## 5. VALUATION

*Informed by: FM #4 (Comps), FM #7 (IC Memo â€” Valuation)*

**Note:** FM #1 (DCF) and FM #2 (Three-Statement) are not applicable â€” zero revenue, no financial statements. FM #3 (LBO) not applicable â€” equity-only VC round, no debt.

### Method 1: Stage-Based Comparable Transactions

| Company | Stage | Geography | Year | Valuation | Adj. for 2026 |
|---------|-------|-----------|:----:|:---:|:---:|
| Codasip seed round | Pre-product, academic | CZ | 2014 | â‚¬2â€“4M | â‚¬3â€“5M (inflation-adj.) |
| SiFive seed | MVP + LOI | US | 2015 | ~$8M | $12M (inflation-adj.) |
| Syntacore early rounds | Pre-product | Russia | 2015 | est. â‚¬3â€“5M | â‚¬4â€“6M (CEE peer) |
| Generic EU deep-tech pre-revenue | Demo stage | EU | 2024-25 | â‚¬3â€“8M | â€” |
| **Implied range** | | | | | **â‚¬3â€“7M** |

### Method 2: Team / IP Premium Adjustment

| Factor | Premium | Justification |
|--------|:-------:|--------------|
| Base (generic deep-tech demo) | â‚¬3M | Median EU pre-revenue deep-tech seed |
| Ciprian exit premium | +â‚¬1.5M | iNoCsâ†’Arteris = validated path in same domain |
| Petru 10yr experience premium | +â‚¬0.5M | Hard-to-replicate technical depth |
| RISC-V timing premium | +â‚¬0.5M | Market tailwind |
| Zero customers discount | -â‚¬0.5M | No commercial validation |
| Romania location discount | -â‚¬0.5M | Non-hub location, talent risk |
| **Adjusted fair value** | | **â‚¬4.5â€“5.5M** |

### Method 3: Future Value Back-Solve

If bull case exit is â‚¬35M in year 7, and V7 needs 3Ã— MOIC:
- V7 must own at minimum: â‚¬1.5M / (â‚¬35M) = 4.3%
- At â‚¬500K investment: implied max cap = â‚¬500K / 4.3% = **â‚¬11.6M**
- At a 30% discount to account for failure probability: **â‚¬8.1M**

This is the *only* methodology that justifies â‚¬8M â€” and it requires the bull case to materialize (20% probability) with no dilution.

### Valuation Football Field

```
Method                          Low          Mid          High
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Stage Comps (CEE adjusted)      â‚¬3.0M  â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘  â‚¬7.0M
Team/IP Premium Adj.            â‚¬4.0M  â–‘â–‘â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘  â‚¬6.5M
Back-solve (3Ã— target)          â‚¬6.0M  â–‘â–‘â–‘â–‘â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ  â‚¬11.6M
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Defensible range                â‚¬3.5M  â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ  â‚¬8.0M
Fiora5 ask                                       â–² â‚¬8.0M
V7 recommended (if investing)   â‚¬4.0M â€” â‚¬5.5M
```

**Conclusion:** â‚¬8M cap is defensible *only* at the high end of a generous range, and only if: (a) power claim is independently verified, (b) no SHA conflict, (c) â‚¬500K is bridge to near-term MVP milestone. At demo stage with no external validation, V7 would negotiate to â‚¬4â€“5.5M cap.

---

## 6. RECOMMENDATION

### â›” PASS â€” Three structural blockers

**Verdict: PASS (Not Watchlist)**

This is not a "come back later with more traction" â€” two of the three blockers are structural for V7 specifically.

---

**Blocker 1 â€” SHA Conflict (FATAL for V7):**

The SHA prohibits investment in weapons, with an exception for non-lethal defense. Fiora5 explicitly targets Lockheed Martin, BAE Systems, and Rheinmetall â€” manufacturers of lethal weapons systems. CPU IP embedded in guided munitions, combat drones, or fire control systems is not "non-lethal defense." This cannot be resolved without:

1. Fiora5 removing all defense customers from their business plan and marketing materials, OR
2. V7 LPs consenting to amend the SHA weapons restriction

Neither is realistic in the near term. **Investment is blocked.**

**Blocker 2 â€” Negative Expected Value at â‚¬8M cap:**

Even in a no-SHA-conflict scenario, the probability-weighted expected return is 0.75Ã—. The combination of high failure probability (35% zero), long time horizon (7+ years), thin ownership at â‚¬500K entry, and small realistic exit size (most likely <â‚¬15M) produces negative EV. Only the low-probability M&A or defense-prime acquisition scenarios justify the investment, and those require the SHA to be amended.

**Blocker 3 â€” V7 Cannot Add Value:**

V7's stated value proposition is to be an "investor of choice" â€” a partner that adds operational, strategic, and network value. V7 has no semiconductor IP industry network, no engineering talent pipeline in this domain, and no experience navigating the 18â€“36 month semiconductor design-win sales cycle. Fiora5 would receive capital and nothing else. The best investors for this deal are: IMEC (EU chip research), EIF (European Investment Fund) via CHIPS Act, NATO Innovation Fund, or a corporate CVC from a defense or semiconductor prime.

---

**What would need to change for a reconsideration:**

| Condition | Current State | Required State |
|-----------|:---:|:---:|
| SHA compatibility | âŒ Defense customers | âœ… Clear business plan excluding lethal applications |
| Technology validation | âŒ Internal claim | âœ… 3rd party power benchmark on FPGA |
| Revenue traction | âŒ Zero | âœ… â‰¥1 LOI or paying pilot |
| Cap | âŒ â‚¬8M at demo | âœ… â‚¬4â€“5M, or â‚¬8M post-MVP validation |
| Runway | âŒ 5â€“7 months | âœ… â‰¥18 months post-raise |
| V7 value-add | âŒ Capital only | âœ… Connector to wearables OEM or edge AI customer |

If Fiora5 pivots away from defense, validates power claims independently, closes one pilot, and comes back at a lower cap â€” V7 could reconsider as a small â‚¬100â€“150K ticket into a larger round led by a specialist investor.

---

## 7. STRATEGY FILE IMPROVEMENTS

*Informed by: gaps identified by applying MC #10 (Risk Assessment), FM #4 (Comps), MC #1 (TAM) to V7's existing files*

The following gaps were identified when applying Robert's institutional framework to a real deal. These are proposed improvements to V7's strategy files.

---

**PROPOSED CHANGE #1:**
```
File: strategy/asymmetry_parameters.md
Section: Pilon 3 â€” Industrie / I1: TAM
Current: Single qualitative rating (ðŸŸ¢/ðŸŸ¡/ðŸ”´) per parameter
Proposed: Require both top-down AND bottom-up TAM calculation for every new deal.
          Format: TAM (top-down) / SAM / SOM (bottom-up) with explicit math.
          Add: 5-year CAGR and source (analyst report or methodology stated).
Rationale: Fiora5's TAM looks large ($5B processor IP) but Fiora5's realistic SOM
           (wearables only, 5-year) is â‚¬500Kâ€“2M ARR â€” a 99%+ reduction. Without
           bottom-up math, TAM ratings are misleading. The Aqurate analysis had the
           same gap (TAM of â‚¬7B for personalization, SOM unstated).
```

---

**PROPOSED CHANGE #2:**
```
File: strategy/asymmetry_parameters.md
Section: Pilon 2 â€” Companie / Risk subsection (missing)
Current: No structured risk scoring matrix in the framework
Proposed: Add a Risk Matrix section to every deal analysis:
          15 risks minimum, scored on Probability (1-5) Ã— Impact (1-5) = Risk Score.
          Require: Early Warning Indicator + Mitigation per risk.
          Top 5 risks presented in IC Memo summary.
Rationale: Applying MC #10 to Fiora5 revealed the SHA conflict (Risk Score 25/25)
           and talent scarcity (25/25) immediately â€” two risks that should have been
           called out in Edi's initial analysis before any meeting time was spent.
           A structured risk matrix would have surfaced the SHA conflict in
           pre-screening.
```

---

**PROPOSED CHANGE #3:**
```
File: strategy/investment_analysis_flow.md
Section: Stage 2 â€” Valuation (currently marked "de dezvoltat")
Current: Stage 2 is a placeholder with no methodology specified.
Proposed: Stage 2 Valuation must include:
          a) Comps analysis: 5+ comparable companies with funding/valuation data
          b) Stage-based benchmarks: what do similarly-staged companies in same
             domain raise at? (CEE-adjusted)
          c) Back-solve: what cap allows V7 to hit target MOIC if bull case
             materializes?
          d) Football field: present all three as a range, not a single number.
          e) Instrument analysis: SAFE vs. CLA vs. equity â€” which is better for V7?
Rationale: The Fiora5 â‚¬8M cap required three distinct methodologies to assess.
           Having a defined Stage 2 process would prevent V7 from anchoring on a
           founder-stated valuation without independent benchmarking.
```

---

**PROPOSED CHANGE #4:**
```
File: strategy/criteria.md
Section: SHA Compliance â€” Pre-Screening Checklist (missing)
Current: criteria.md does not include SHA restriction screening.
Proposed: Add a mandatory SHA pre-screen as Step 0 before any analysis begins:
          â–¡ Weapons / lethal defense systems? (SHA: NO, except non-lethal defense)
          â–¡ Gambling? (SHA: NO)
          â–¡ Tobacco? (SHA: NO)
          â–¡ Crypto/digital assets as primary business? (SHA: NO)
          â–¡ Real estate as primary business? (SHA: NO)
          â–¡ Adult entertainment? (SHA: NO)
          If any check fails â†’ PASS immediately. No analysis required.
Rationale: Fiora5 required full analysis (Edi's meeting + pitch deck review +
           analysis file) before the SHA conflict was formally called out. A
           2-minute SHA pre-screen would have saved that time.
```

---

**PROPOSED CHANGE #5:**
```
File: strategy/investment_framework.md
Section: Post-Mortem Template
Current: Template includes "ce am scris la pre-investiÈ›ie?" and "ce s-a Ã®ntÃ¢mplat?"
Proposed: Add a "Deals We Passed" section alongside portfolio post-mortems:
          - Why did we pass? (specific reasons, not generic)
          - What happened to the company in 1-2-3 years?
          - Was our reasoning correct?
          - What would we do differently?
Rationale: Workshop noted this explicitly: "È™i companiile pe care le REFUZÄ‚M trebuie
           documentate." The framework doesn't currently have a structured template
           for tracking refused deals. Fiora5 should be filed in a Deals Refused
           tracker with a review date of 18.02.2027.
```

---

## 8. HOW THIS ANALYSIS HELPS V7 CAPITAL

### What was unclear before â€” what is clear now

| Question | Before (Edi analysis) | After (Robert framework) |
|----------|----------------------|--------------------------|
| Is the SHA conflict real? | âœ… Flagged | âœ… Quantified as Risk Score 25/25 â€” highest possible |
| Is the â‚¬8M cap fair? | "SuprapreÈ›" qualitative | Benchmarked against 5 comps. Fair range: â‚¬3.5â€“5.5M. Overpriced by 45â€“130% |
| What is the expected return? | Described as "negative" | Calculated: E[MOIC] = 0.75Ã— â€” negative EV even without SHA |
| How big is Fiora5's real market? | "PiaÈ›Äƒ Ã®n creÈ™tere" | SOM (wearables, Y5) = â‚¬500Kâ€“2M ARR. Small without defense |
| What are the kill scenarios? | "Orizont 10-15 ani" | 3 kill scenarios identified with triggers and early warning indicators |
| Who should invest in Fiora5 instead? | Not addressed | NATO Innovation Fund, EU CHIPS Act grants, defense CVC (Airbus Ventures, BAE Systems Digital) |

### Which strategy files should be updated

1. **`criteria.md`** â€” Add SHA pre-screen checklist (immediate action, 30 min work)
2. **`asymmetry_parameters.md`** â€” Add bottom-up TAM requirement + risk matrix
3. **`investment_analysis_flow.md`** â€” Build out Stage 2 Valuation methodology
4. **`investment_framework.md`** â€” Add Deals Refused tracker template

### Information gaps â€” what remains unknown

| Gap | Owner | How to close |
|-----|-------|-------------|
| Is the 50% power reduction claim real? | Technical | Independent review: share architecture with semiconductor academic (TU Dresden, IMEC) |
| What is Darian's commercial background? | Edi | LinkedIn deep-dive + reference call with someone who has worked with him |
| SAFE vs. CLA â€” which is the actual instrument? | Edi | Ask Fiora5 directly in next touchpoint |
| iNoCs â†’ Arteris exit terms (Ciprian's actual payout) | Robert | AngelList, Crunchbase, court filings in CH if public |
| EU CHIPS Act grant eligibility for Fiora5 | Elena legal | 30-min call with EU funding advisor |
| NATO Innovation Fund interest in RISC-V IP | â€” | Would only be relevant if V7 co-invests alongside or refers |

### Referral recommendation

**Refer Fiora5 to:**
1. **NATO Innovation Fund** (NIF, Luxembourg) â€” specifically invests in dual-use deep tech. RISC-V defense electronics is core mandate.
2. **EIF via EU CHIPS Act** â€” non-dilutive grant capital for European semiconductor IP startups
3. **Underline Ventures** (Bogdan already in contact per notes) â€” Romanian VC with higher risk appetite and smaller tickets
4. **Airbus Ventures / BAE Systems Digital** â€” CVC arms that can absorb SHA-incompatible defense bets

Referring well, even on a pass, is part of V7's "investor of choice" positioning.

---

*Analysis produced using Robert's Deep Analysis framework (Robert/notes/prompt.md). Financial Models prompts: FM #4, FM #7. Management Consulting prompts: MC #1, MC #2, MC #4, MC #5, MC #9, MC #10, MC #12. Underlying data: Pitch Deck Fiora5 (feb 2026), NotiÈ›e Edi (meeting fondatori), SHA V7 Capital, V7 strategy files (asymmetry_parameters.md v3.1, investment_framework.md, investment_analysis_flow.md). All financial projections are estimates based on comparable transactions and stated assumptions â€” not audited data.*
